BioCentury
ARTICLE | Clinical News

RVSV-EBOV: Phase III started

March 23, 2015 7:00 AM UTC

The World Health Organization (WHO) began an open-label, Guinea Phase III trial to evaluate VSV-EBOV from NewLink and Merck in about 10,000 adults. Subjects will be recruited based on a ring system, allowing contacts of the newly diagnosed Ebola patients to be vaccinated immediately while other contacts will be vaccinated 3 weeks later. Medecins Sans Frontieres (MSF), the Research Council of Norway, the Canadian government, WHO and the Wellcome Trust are funding the trial. ...